Mylan's Antitrust Law Violation: What You Need To Know

Mylan, a pharmaceutical company, has been under scrutiny for possible antitrust law violations in the United States. The allegations centre around Mylan's EpiPen sales practices, particularly its EpiPen4Schools program, which offered discounted or free EpiPens to schools. To qualify for the discounted price, schools had to agree not to purchase any competing products for a year, a provision that experts argue may have violated antitrust laws by hindering competition. Mylan has also been investigated for underpaying EpiPen rebates and price-fixing generic drugs, resulting in a $465 million settlement and a $38.7 million whistleblower reward. While Mylan has denied any wrongdoing, the investigations and their outcomes highlight the importance of maintaining fair competition and protecting consumers in the pharmaceutical industry.

Mylan's EpiPen4Schools program

Anaphylaxis is a potentially life-threatening allergic reaction that can occur quickly and without warning. The rate of reported severe allergic reactions to food alone has increased by nearly five times over the past decade. According to a recent independent study, one in three patients prescribed epinephrine did not carry their medication during a reported anaphylactic event, demonstrating the need for programs like EpiPen4Schools.

Since its launch, more than 73,000 schools have participated in the program, which accounts for approximately 54% of the nation's schools. The program has also surpassed one million free epinephrine auto-injector donations. The auto-injectors provided through the program have been used over 2,000 times to treat anaphylaxis in schools since 2014.

In the 2015-2016 school year, more than 1,500 anaphylactic events were reported by over 8,000 schools. An epinephrine auto-injector was used in 83% of these events, and nearly 60% of the time, the auto-injector was provided by the EpiPen4Schools program. The data shows an improvement in the use of epinephrine auto-injectors to treat anaphylaxis and highlights the importance of the program in providing access to potentially life-saving medication in schools.

Mylan has faced legal scrutiny for its pricing and marketing practices related to the EpiPen and has been involved in settlements and investigations regarding antitrust and false claims allegations. However, the focus of the question is on the EpiPen4Schools program, and it is important to note that this program has been recognized for its positive impact in providing access to epinephrine auto-injectors in schools.

Antitrust investigations into Mylan

Mylan, a pharmaceutical company, has been under investigation by the US Department of Justice (DOJ) for possible antitrust law violations. The investigation focused on Mylan's pricing and marketing practices for its generic doxycycline antibiotic drug and its EpiPen sales to schools.

In July 2024, it was reported that the DOJ had dropped its antitrust probe into Mylan's parent company, Viatris, regarding alleged price-fixing in the generic drug industry. Mylan and several major drugmakers were accused of engaging in anticompetitive business practices by fixing prices for certain generic drugs. However, the DOJ informed Viatris that it did not expect to take any further action related to the pricing and sales of its generic drugs.

Mylan's "EpiPen4Schools" program, launched in August 2012, offered free or discounted EpiPens to schools across the country. While the program provided financial relief to schools facing rising costs, it also included a controversial provision that prohibited schools from purchasing competitors' devices. This restriction, according to experts, may have violated antitrust laws.

The agreement stipulated that schools, in order to qualify for the discounted price, had to agree not to purchase any products competitive with EpiPen auto-injectors for the next 12 months. This type of exclusionary contract, according to Herbert Hovenkamp, a University of Iowa law professor and antitrust expert, is illegal if it substantially lessens competition. Mylan's dominant market share in the epinephrine auto-injector market, combined with such exclusionary contracts, may have hindered competition and violated antitrust laws.

In addition to the DOJ investigation, multiple states have also filed lawsuits against Mylan and other companies for alleged antitrust behaviour.

Mylan's pricing and marketing of generic drugs

Mylan, a global generic and specialty pharmaceuticals company, has been accused of engaging in anticompetitive business practices and price-fixing in the generic drug industry. The US Department of Justice (DOJ) investigated Mylan's pricing and marketing of its generic doxycycline antibiotic, which is used to treat various bacterial infections. The investigation spanned more than eight years and included other major drugmakers such as Teva Pharmaceutical Industries and Sun Pharmaceutical Industries.

Mylan's practices came under scrutiny as they were allegedly fixing prices for certain generic drugs. The company's pricing strategy for its EpiPen product also attracted criticism and led to a settlement with the US government. Between 2009 and 2016, Mylan raised the price of EpiPens by approximately 500%, from about $100 for two EpiPens to around $600. This price increase sparked widespread outrage, particularly as there were no competitors on the market for this life-saving allergy treatment.

In response to the backlash, Mylan announced it would offer a generic version of the EpiPen at half the cost of its brand-name product. However, this move was seen by some as a marketing ploy, as the generic price was still considered too high. Mylan's handling of the EpiPen pricing and its attempts to maintain market dominance were scrutinized, and the company faced additional investigations and lawsuits.

In 2017, Mylan agreed to pay $465 million to resolve claims that it had violated the False Claims Act by misclassifying EpiPen as a generic drug to avoid paying higher rebates to Medicaid. This settlement also addressed allegations related to underpaying rebates under the Medicaid Drug Rebate Program for other drugs.

In 2024, the DOJ dropped Mylan from its antitrust investigation into price-fixing, but the company continued to face civil lawsuits related to its generic drug pricing and marketing practices.

Mylan's EpiPen sales to schools

Mylan's EpiPen4Schools program, which began in August 2012, offers free or discounted EpiPens to schools. Over 65,000 schools receive free EpiPens through the program, and an unknown number of schools buy the epinephrine auto-injectors at a discount. The discounted price was $112.10, which is about a quarter of the cost charged to pharmacies.

However, to qualify for that discounted price, schools had to agree that they would "not in the next twelve (12) months purchase any products that are competitive to EpiPen(R) Auto-Injectors." This agreement was removed from the EpiPen4Schools website, and a Mylan spokesperson said that this requirement is no longer part of its program.

Legal experts say that this requirement may have violated antitrust law. Herbert Hovenkamp, a University of Iowa law professor and antitrust expert, said that "it is illegal to issue a discount on the condition the customer not acquire a competitor's goods — if the effect may be to substantially lessen competition."

In response to concerns raised by Senator Amy Klobuchar, an FTC spokesperson said that "the Commission takes seriously its obligation to take action where pharmaceutical companies have violated the antitrust laws, and it will continue to closely scrutinize drug market competition on consumers' behalf."

Mylan has since been removed from an industry-wide antitrust probe by the US Department of Justice.

Mylan's alleged price fixing

Mylan has been at the centre of several lawsuits and investigations into alleged price-fixing and anticompetitive business practices.

In 2017, Mylan President Rajiv Malik was named in a high-profile price-fixing lawsuit brought by several US states. The lawsuit alleged that Mylan, Teva Pharmaceutical, and several other leading generic drugmakers had colluded to fix prices. According to the lawsuit, companies met at industry events and social gatherings to divvy up markets and agree on prices. While Mylan has denied any wrongdoing, the company has faced federal and state investigations into its pricing practices.

In addition to the federal probe, multiple US states have filed lawsuits against Mylan and other drugmakers for alleged antitrust behaviour. One such lawsuit, approved by the United States District Court for the District of Kansas in 2022, accused Mylan of engaging in "anticompetitive conduct" in the marketing and sales of its EpiPen product. The plaintiffs claimed that Mylan used tactics such as discount agreements and excessive rebates to dramatically raise the price of EpiPen, resulting in consumers paying exorbitant prices.

Mylan has also faced scrutiny for its pricing and marketing of its generic doxycycline antibiotic. The US Department of Justice (DOJ) investigated Mylan for allegedly fixing prices and engaging in anticompetitive practices for this drug. However, in 2024, the DOJ dropped Mylan from the industry-wide antitrust probe without providing further details.

While Mylan has denied any wrongdoing and defended itself against the allegations, the company has faced significant backlash and scrutiny for its pricing practices.

Frequently asked questions